CORD-19:12d35c12218f230c49f4dc892814ba9f1037f251 / 61451-61674
Annnotations
CORD-19_Custom_license_subset
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T55 | 0-223 | Sentence | denotes | To this end, toxicity trials in non-human primates have already demonstrated that agonistic OX40 antibody therapy is well tolerated and safe, therefore providing a strong rationale to pursue clinical tests in humans (168) . |
CORD-19-Sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T22135 | 0-223 | Sentence | denotes | To this end, toxicity trials in non-human primates have already demonstrated that agonistic OX40 antibody therapy is well tolerated and safe, therefore providing a strong rationale to pursue clinical tests in humans (168) . |